Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB‐506 from Phase 1 studies in healthy subjects and those with hepatitis B
Man‐Fung Yuen, Elina Berliba, Wattana Sukeepaisarnjaroen, et al.
Hepatology Communications (2022) Vol. 6, Iss. 12, pp. 3457-3472
Open Access | Times Cited: 21

Showing 21 citing articles:

New Perspectives on Development of Curative Strategies for Chronic Hepatitis B
Jordan J. Feld, Anna S. Lok, Fabien Zoulim
Clinical Gastroenterology and Hepatology (2023) Vol. 21, Iss. 8, pp. 2040-2050
Open Access | Times Cited: 31
Rational Design, Synthesis, and Structure–Activity Relationship of a Novel Isoquinolinone-Based Series of HBV Capsid Assembly Modulators Leading to the Identification of Clinical Candidate AB-836
Andrew G. Cole, Steven G. Kultgen, Nagraj Mani, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 18, pp. 16773-16795
Closed Access | Times Cited: 6
The Hepatitis B Virus Nucleocapsid—Dynamic Compartment for Infectious Virus Production and New Antiviral Target
Matthias Niklasch, Peter Jan Zimmermann, Michael Nassal
Biomedicines (2021) Vol. 9, Iss. 11, pp. 1577-1577
Open Access | Times Cited: 39
Novel mechanistic insights – A brand new Era for anti-HBV drugs
Weiping Lyu, Haoming Qin, Qi Li, et al.
European Journal of Medicinal Chemistry (2024) Vol. 279, pp. 116854-116854
Closed Access | Times Cited: 4
Discovery of AIC263282, a Hepatitis B Virus Capsid Assembly Modulator Ready for Candidate Profiling
B. Lesch, Alexander Birkmann, Susanne Bonsmann, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Synthesis and evaluation of N-sulfonylpiperidine-3-carboxamide derivatives as capsid assembly modulators inhibiting HBV in vitro and in HBV-transgenic mice
Jiaxin Yin, Zhongqi Feng, Zhi Li, et al.
European Journal of Medicinal Chemistry (2023) Vol. 249, pp. 115141-115141
Closed Access | Times Cited: 6
Design, synthesis, and structure-activity relationship of a bicyclic HBV capsid assembly modulator chemotype leading to the identification of clinical candidate AB-506
Andrew G. Cole, Steven G. Kultgen, Nagraj Mani, et al.
Bioorganic & Medicinal Chemistry Letters (2023) Vol. 94, pp. 129456-129456
Closed Access | Times Cited: 6
Opportunities and challenges for hepatitis B cure
Armando Andres Roca Suarez, Fabien Zoulim
eGastroenterology (2023) Vol. 1, Iss. 2, pp. e100021-e100021
Open Access | Times Cited: 6
Conformationally Constrained Isoquinolinones as Orally Efficacious Hepatitis B Capsid Assembly Modulators
Eugen F. Mesaros, Andrew G. Cole, Steven G. Kultgen, et al.
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 9, pp. 1627-1634
Closed Access | Times Cited: 1
Preclinical and Clinical Antiviral Characterization of AB-836, a Potent Capsid Assembly Modulator Against Hepatitis B Virus
Angela M. Lam, Nagraj Mani, Andrzej Ardzinski, et al.
Antiviral Research (2024), pp. 106010-106010
Closed Access | Times Cited: 1
Advances in determining new treatments for hepatitis B infection by utilizing existing and novel biomarkers
Lung‐Yi Mak, Rex Wan‐Hin Hui, Ka Shing Cheung, et al.
Expert Opinion on Drug Discovery (2023) Vol. 18, Iss. 4, pp. 401-416
Closed Access | Times Cited: 3
Test All for Hepatitis B Virus
Katerina Roma, Zahra Dossaji, Lubaba Haque, et al.
Clinics in Liver Disease (2023) Vol. 27, Iss. 4, pp. 997-1022
Closed Access | Times Cited: 3
Preclinical characterization of ABI-H2158, an HBV core inhibitor with dual mechanisms of action
Ran Yan, Dawei Cai, Yuhua Zong, et al.
Antiviral Research (2022) Vol. 209, pp. 105485-105485
Closed Access | Times Cited: 5
A Review of the Systemic Manifestations of Hepatitis B Virus Infection, Hepatitis D Virus, Hepatocellular Carcinoma, and Emerging Therapies
Katerina Roma, Toni-Marie Chandler, Zahra Dossaji, et al.
Gastro Hep Advances (2023) Vol. 3, Iss. 2, pp. 276-291
Open Access | Times Cited: 2
Discovery of novel small molecules targeting hepatitis B virus core protein from marine natural products with HiBiT-based high-throughput screening
Chao Huang, Yang Jin, Panpan Fu, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 11, pp. 4914-4933
Open Access
Preclinical and Clinical Antiviral Characterization of Ab-836, a Potent Capsid Assembly Modulator Against Hepatitis B Virus
Angela M. Lam, Nagraj Mani, Andrzej Ardzinski, et al.
(2024)
Closed Access
The roadmap towards cure of chronic hepatitis B virus infection
Edward Gane
Journal of the Royal Society of New Zealand (2020) Vol. 52, Iss. 2, pp. 129-148
Closed Access | Times Cited: 3
Future of Chronic Hepatitis B Infection Therapies
Katerina Roma, Robert G. Gish
Gastro Hep Advances (2023) Vol. 2, Iss. 4, pp. 556-557
Open Access | Times Cited: 1
Evidence-Based Strategies for Micro-elimination of Chronic Hepatitis B Virus Infection
Katerina Roma, Mark Hsu, Adam Khattak, et al.
Current Hepatology Reports (2023) Vol. 22, Iss. 3, pp. 118-129
Open Access | Times Cited: 1
Surveillance Following Hepatitis B Surface Antigen Loss: An Issue Requiring Attention
Shuai-Wen Huang, Hong Long, Jiaquan Huang
Pathogens (2024) Vol. 14, Iss. 1, pp. 8-8
Open Access
Page 1

Scroll to top